InvestSMART

Imugene Limited (ASX: IMU) - Announcements

- Current share price for IMU : $0.082

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$40 Notice of Annual General Meeting/Proxy Form 14 Oct 2024 4:28PM $0.053 $0.082 risen by 54.72%
$40 Change of Director's Interest Notice - PH 30 Sep 2024 5:01PM $0.049 $0.082 risen by 67.35%
$40 Imugene Receives Orphan Drug Designation for VAXINIA 18 Sep 2024 1:06PM $0.051 $0.082 risen by 60.78%
$40 Appendix 2A 11 Sep 2024 4:59PM $0.053 $0.082 risen by 54.72%
$40 Imugene Corporate Presentation 9 Sep 2024 10:12AM $0.052 $0.082 risen by 57.69%
$40 Cleansing Notice 4 Sep 2024 4:32PM $0.059 $0.082 risen by 38.98%
$40 Application for quotation of securities - IMU 4 Sep 2024 4:29PM $0.059 $0.082 risen by 38.98%
$40 Imugene Azer-cel Webinar Presentation 4 Sep 2024 10:19AM $0.062 $0.082 risen by 32.26%
$40 Imugene Webinar - Azer-cel Trial Update 3 Sep 2024 8:26AM $0.068 $0.082 risen by 20.59%
$40 Three Complete Responses in Azer-Cel Phase 1b Trial 2 Sep 2024 8:44AM $0.062 $0.082 risen by 32.26%
$40 Imugene ESG Report 2024 30 Aug 2024 6:44PM $0.062 $0.082 risen by 32.26%
$40 Corporate Governance Statement 2024 and Appendix 4G 30 Aug 2024 6:43PM $0.062 $0.082 risen by 32.26%
$40 Appendix 4E and Annual Report 30 Aug 2024 6:43PM $0.062 $0.082 risen by 32.26%
$40 Release of Shares from Voluntary Escrow 2 Aug 2024 5:59PM $0.052 $0.082 risen by 57.69%
$40 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2024 9:16AM $0.053 $0.082 risen by 54.72%
$40 Notification of cessation of securities - IMU 12 Jul 2024 5:28PM $0.059 $0.082 risen by 38.98%
$40 Notification regarding unquoted securities - IMU 12 Jul 2024 5:19PM $0.059 $0.082 risen by 38.98%
$40 First patient dosed in Phase 1 bile tract cancer trial 10 Jul 2024 9:20AM $0.051 $0.082 risen by 60.78%
$40 Change of Director's Interest Notice x6 8 Jul 2024 4:50PM n/a $0.082 n/a
$40 Application for quotation of securities - IMU 8 Jul 2024 11:20AM n/a $0.082 n/a
$40 Imugene Corporate Presentation 4 Jul 2024 3:44PM n/a $0.082 n/a
$40 Imugene onCARlytics Doses First Patient in IV Combination 24 Jun 2024 8:24AM $0.059 $0.082 risen by 38.98%
$40 Imugene Presentation to Bell Potter Conference 30 May 2024 12:06PM $0.068 $0.082 risen by 20.59%
$40 Application for quotation of securities - IMU 6 May 2024 4:10PM $0.077 $0.082 risen by 6.49%
$40 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2024 8:48AM $0.082 $0.082 fallen by 0%

201 - 225 of 1186 results

Page 9 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.